Details:
PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). It is being evaluated for the treatment of gout flares.
Lead Product(s): Colchicine,Ropivacaine Hydrochloride
Therapeutic Area: Rheumatology Product Name: PKM-01
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
ABP-745 is an oral small molecule drug which is being evaluated for the treatment of acute gout. Preclinical trials showed that it can significantly reduce levels of inflammatory factors & compared with similar drugs, it has good efficiency & significant safety improvement.
Lead Product(s): ABP-745
Therapeutic Area: Rheumatology Product Name: ABP-745
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria.
Lead Product(s): SYNB2081
Therapeutic Area: Rheumatology Product Name: SYNB2081
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Ginkgo Bioworks
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022